Upload Avatar (500 x 500)
Jing Yang
Life Science
Tongji University
Shanghai
Language: Chinese, English
Leukemia
Malignant Diseases
Targeted Therapy
Immunotherapy
Protein Degradation
Dub
E3 Ligases
Drug Discovery
Resistance Mechanisms
Clinical Development
Areas of Focus
- Targeted and immunotherapy for malignant diseases such as leukemia
- Discovery and development of first-in-class targeted degraders
Work Experience
- 2015-2020 - Dana-Farber Cancer Institute, Harvard Medical School: Postdoctoral Training
- 2021 Jan-Aug - Hefei Institutes of Physical Science, Chinese Academy of Sciences: Associate Researcher
- 2022 Sep-Present - Tongji University, School of Life Sciences and Technology: Distinguished Researcher
Academic Background & Achievements
- 2009 - Bachelor of Science: Shandong University
- 2015 - Doctor of Science: Shanghai Pasteur Institute, Chinese Academy of Sciences
- Identified several pathogenic protein degradation targets DUB/E3 during doctoral studies
Publications
- Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-COV-2, Jing Yang et al., 2023
- Gilteritinib: Repurposing of AXL-targeting kinase inhibitors against COVID-19, Jing Yang et al., 2023
- Discovery of IHMT-337 as a potent irreversible inhibitor targeting novel noncanonical role of EZH2 for triple-negative breast cancer, Jing Yang et al., 2023
- Inhibition of deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2, Jing Yang et al., 2022
- Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2, Jing Yang et al., 2022
- The deubiquitinase USP44 promotes Treg function during inflammation by preventing FOXP3 degradation, Jing Yang et al., 2020
- Inhibition of the deubiquitinase USP10 induces degradation of SYK, Jing Yang et al., 2020
- HSP70 and FLT3-ITD: targeting chaperone system to overcome drug resistance, Jing Yang et al., 2021
- Ubiquitin-Specific Protease 4 Promotes Th17 Cell Function under Inflammation by Deubiquitinating and Stabilizing RORγt, Jing Yang et al., 2015
- TRAF5 Mediated K63-linked Polyubiquitination Plays an Essential Role in the Positive regulation of RORγt on promoting IL-17A Expression, Jing Yang et al., 2015
- The E3 deubiquitinase USP17 is a positive regulator of retinoic acid-related orphan nuclear receptor γt (RORγt) in Th17 cells, Jing Yang et al., 2014
